Below is a list of agents under investigation for the treatment of lymphoid malignancies. Information was gathered from ClinicalTrials.gov, as well as the respective drug manufacturers. Unless otherwise stated, these agents are being investigated in the relapsed and/or refractory disease setting. For a comprehensive list of agents being evaluated for these conditions, please consult ClinicalTrials.gov.
Phosphatidylinositide 3 Kinase (PI3K) Inhibitors
Apilimod dimesylate: a PIKfyve inhibitor for non-Hodgkin lymphoma (NHL)
Bimiralisib: an oral selective dual PI3K/mTOR inhibitor in preclinical lymphoma models
Buparlisib: a small molecule orally-available PI3K inhibitor for diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and FL
Duvelisib: a PI3Kδ and PI3Kγ inhibitor for previously untreated CD20-positive follicular lymphoma (FL)
Kinase Inhibitors
BGB-3111: a Bruton tyrosine kinase (BTK) inhibitor for DLBCL
ONC201: an Akt/ERK inhibitor for the treatment of MCL and DLBCL
SNS-062: a BTK inhibitor for CLL, small lymphocytic lymphoma (SLL), MCL, DLBCL, and FL
Monoclonal Antibodies
AFM13: an anti-CD30 and anti-CD16A bispecific antibody for CD30-positive lymphomas
Cirmtuzumab: an anti-ROR1 monoclonal antibody for B-cell chronic lymphocytic leukemia, SLL, and MCL
Epratuzumab: an anti-CD22 monoclonal antibody for previously untreated FL and NHL
Isatuximab: an anti-CD38 monoclonal antibody for MM
Mogamulizumab: an anti-CCR4 monoclonal antibody for cutaneous T-cell lymphoma
Tremelimumab: an anti-CTLA4 monoclonal antibody for MM
Checkpoint Inhibitors
Atezolizumab: an anti-programmed death-ligand 1 (anti-PD-L1) inhibitor for MM
Durvalumab: an anti-PD-L1 inhibitor for MM
TTI-621: a CD47-targeting recombinant fusion protein for DLBCL
Antibody Drug Conjugates (ADC)
AGS67E: an anti-CD37 ADC for NHL
GSK2857916: an anti B-cell maturation agent (BCMA) monoclonal ADC for MM
Polatuzumab vedotin: an anti-CD79b ADC for DLBCL and FL
SGN-CD352A: an anti-CD352 ADC for MM
SGN-CD48A: an anti-CD48 ADC for MM
T-Cell Therapy
ACTR087: an autologous T-cell product for MM
bb2121: an anti-BCMA CAR T-cell therapy for MM
BI 836909: a bispecific T-cell engager (BiTE) targeting BCMA and CD3É› for MM
SINE XPO1 Antagonist
Selinexor: a first-in-class SINE XPO1 antagonist
Immunomodulatory Drugs
CC-220: a cereblon-binding immunomodulator